Mekonos

About:

Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip.

Twitter/X: mekonosinc

Top Investors: Creative Destruction Lab (CDL), Novartis, Sands Capital Ventures, Section 32, Debiopharm Innovation Fund

Description:

Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip. Mekonos is a Silicon Valley Venture-backed technology company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in drug discovery and development.

Total Funding Amount:

$31M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Alameda, California, United States

Founded Date:

2017-05-01

Founders:

Anil Narasimha, Greg Sitters, Milad Alucozai, Steven Banerjee

Number of Employees:

11-50

Last Funding Date:

2021-11-09

IPO Status:

Private

Industries: